Skip to content

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02519621
Enrollment
90
Registered
2015-08-11
Start date
2016-04-30
Completion date
2020-06-24
Last updated
2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partial-thickness Burn, Ulcer

Keywords

diabetic ulcer, pressure ulcer, chronic or traumatic wound, sub-acute or dehisced wound

Brief summary

This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes. It is also designed to assess the effectiveness of negative pressure and negative pressure with continuous irrigation on multiple parameters of wound healing. It is a single-center, open-label, active controlled, parallel-group trial that aims to determine the efficacy of Quantum with simultaneous irrigation in the treatment of diabetic foot ulcers. Specifically, eligible participants will be randomized to receive either PRO negative press therapy with simultaneous irrigation; or PRO negative pressure therapy without irrigation; or KCI Ulta negative pressure therapy. Outcomes will include rates of wound healing, time to closure, number of surgeries, length of stay, and days to heal.

Detailed description

Subjects will be taken to the operating room for the initial debridement procedure of the wound. At the end of the procedure, subjects who continue to meet all inclusion and no exclusion criteria will be randomized in a 1:1:1 ratio to be treated with either PRO, PRO with simultaneous irrigation (PROI), or KCI Ulta NPWT. Prior to study initiation sealed prenumbered randomization envelopes will be provided to the research staff and used to obtain randomization assignment. Opening of the randomization envelope will occur intraoperatively at the conclusion of the initial surgical debridement of the wound and conformation of all eligibility requirements. Study staff will use the randomization number labels contained in the envelop. The number will become the subject ID. The assignment will be subjects randomized to PRO, PRO with simultaneous irrigation, or KCI Ulta NPWT. The research staff will note treatment assignments on the intra operative randomization CRF and instruct the investigator. Treatment therapy wound dressings will be applied in the operating room or in the patient's room immediately after surgery per the investigators discretion, according to the manufacturer's recommendations. In order to ensure consistent study treatment, subjects will receive assigned treatment therapies within their study arm after the initial and any subsequent surgical debridements until the wound is deemed ready for closure or coverage by the Investigator. Subjects randomized to the PRO with simultaneous irrigation Treatment arm are the only subjects that will receive irrigation therapy at any time during the study treatment period. If irrigation therapy is discontinued, subjects in the Treatment arm will transition to PRO NPWT without irrigation. Subjects randomized to the PRO Control arm will receive NPWT only from the PRO therapy unit.

Interventions

DEVICENPWT PRO without irrigation

NPWT PRO without irrigation.

DEVICENPWT PRO with irrigation

NPWT PRO with irrigation (saline)

DEVICEKCI Ulta

KCI Ulta NPWT without irrigation

Sponsors

Larry Lavery
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Presents with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M) * Wound presents with full thickness loss of epidermis and dermis * The presentation of a wound that in the opinion of the investigators will require surgical debridement, and the wound is expected to be a good candidate for NPWT and eventual wound closure. * ABI≥0.5 or toe pressures \>30 PVR/mmHg * Subject is willing and able to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described herein. * 18 years of age or older

Exclusion criteria

* Does not present with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft, or a definitive diagnosis cannot be made, as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M) * Wound does not present with full thickness loss of epidermis and dermis * ABI\<0.5 or toe pressures \<30 PVR/mmHg * Subject is not willing or is not able or it is not medically prudent for the subject to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described. * Subject is unwilling or unable to use the NPWT device at home * Active Charcot arthropathy * Collagen vascular disease * Scleroderma * Non-enteric and unexplored fistula * Necrotic tissue with eschar present after debridement * General skin disorder in the area of the wound such as psoriasis or penicilitis * Malnutrition (defined as BMI \<19) * Hypercoagulable state based on documentation in their medical record * Acute deep vein thrombosis * Current active malignancy in the wound * Current melanoma or history of melanoma at the wound * Current active or history of invasive squamous cell carcinoma at the wound * Sepsis (defined as positive blood culture with leukocytosis) and temperature \>101.5 at the time of screening * Significant Hematologic disorders EXCLUDING anemia * HIV * Fever at screening \> 101.5 * Deep X-ray therapy * Untreated bone or soft tissue infection (osteomyelitis) * Any concomitant illness(es) or medical condition(s) that in the opinion of the investigator would render the subject not suited for study participation * Subject is taking a regimen of any medication(s) in a significant enough dosage that may affect chronic wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications * Less than 18 years of age * Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years. * Females currently pregnant or planning pregnancy during the course of intended participation in the study * Active alcohol or substance abuse in the opinion of the investigator that could impair the subjects ability to provide informed consent, participate in the study protocol or record study measures.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Achieved Complete Wound Healing12 weeksComplete healing of wounds as defined by epithelialization with no drainage in three treatment arms: NPWT PRO versus KCI Ulta® NPWT and to Compare NPWT PRO versus NPWT PRO with Simultaneous Irrigation

Secondary

MeasureTime frameDescription
Number of Surgeries12 weeksNumber of surgeries required to debride infection before wound was ready for closure or coverage.
Length of Stay12 weeksNumber of days the patient stayed in the hospital
Days to Heal12 weeksThe number of days to heal the wound after last surgery was performed.

Countries

United States

Participant flow

Pre-assignment details

93 were consented but 3 of them did not have the vac/treatment, so therefore 90 total (30 in each group).

Participants by arm

ArmCount
NPWT PRO Without Irrigation
Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage NPWT PRO without irrigation: NPWT PRO without irrigation.
30
NPWT PRO With Irrigation
Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant). NPWT PRO with irrigation: NPWT PRO with irrigation (saline)
30
KCI Ulta NPWT
KCI Ulta NPWT without irrigation. KCI Ulta: KCI Ulta NPWT without irrigation
30
Total90

Baseline characteristics

CharacteristicNPWT PRO Without IrrigationNPWT PRO With IrrigationKCI Ulta NPWTTotal
Age, Continuous49.50 years
STANDARD_DEVIATION 9.95
53.80 years
STANDARD_DEVIATION 12.21
51.70 years
STANDARD_DEVIATION 9.44
51.67 years
STANDARD_DEVIATION 10.63
Race/Ethnicity, Customized
African American
4 Participants9 Participants1 Participants14 Participants
Race/Ethnicity, Customized
Caucasian
10 Participants1 Participants5 Participants16 Participants
Race/Ethnicity, Customized
Hispanic
16 Participants20 Participants24 Participants60 Participants
Region of Enrollment
United States
30 participants30 participants30 participants90 participants
Sex: Female, Male
Female
5 Participants7 Participants4 Participants16 Participants
Sex: Female, Male
Male
25 Participants23 Participants26 Participants74 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 300 / 300 / 30
other
Total, other adverse events
4 / 305 / 305 / 30
serious
Total, serious adverse events
4 / 304 / 304 / 30

Outcome results

Primary

Number of Participants Who Achieved Complete Wound Healing

Complete healing of wounds as defined by epithelialization with no drainage in three treatment arms: NPWT PRO versus KCI Ulta® NPWT and to Compare NPWT PRO versus NPWT PRO with Simultaneous Irrigation

Time frame: 12 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
NPWT PRO Without IrrigationNumber of Participants Who Achieved Complete Wound Healing15 Participants
NPWT PRO With IrrigationNumber of Participants Who Achieved Complete Wound Healing19 Participants
KCI Ulta NPWTNumber of Participants Who Achieved Complete Wound Healing14 Participants
Secondary

Days to Heal

The number of days to heal the wound after last surgery was performed.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
NPWT PRO Without IrrigationDays to Heal41.0 daysStandard Deviation 6.3
NPWT PRO With IrrigationDays to Heal43.0 daysStandard Deviation 9.4
KCI Ulta NPWTDays to Heal42.0 daysStandard Deviation 13.1
Secondary

Length of Stay

Number of days the patient stayed in the hospital

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
NPWT PRO Without IrrigationLength of Stay14.7 daysStandard Deviation 7.4
NPWT PRO With IrrigationLength of Stay16.3 daysStandard Deviation 15.7
KCI Ulta NPWTLength of Stay15.3 daysStandard Deviation 10.5
Secondary

Number of Surgeries

Number of surgeries required to debride infection before wound was ready for closure or coverage.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
NPWT PRO Without IrrigationNumber of Surgeries2.4 surgeriesStandard Deviation 0.77
NPWT PRO With IrrigationNumber of Surgeries2.0 surgeriesStandard Deviation 0.49
KCI Ulta NPWTNumber of Surgeries2.4 surgeriesStandard Deviation 0.68

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026